Your browser doesn't support javascript.
loading
Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).
Kuo, Phillip H; Morris, Michael J; Hesterman, Jacob; Kendi, A Tuba; Rahbar, Kambiz; Wei, Xiao X; Fang, Bruno; Adra, Nabil; Garje, Rohan; Michalski, Jeff M; Chi, Kim; de Bono, Johann; Fizazi, Karim; Krause, Bernd; Sartor, Oliver; Tagawa, Scott T; Ghebremariam, Samson; Brackman, Marcia; Wong, Connie C; Catafau, Ana M; Benson, Taylor; Armstrong, Andrew J; Herrmann, Ken.
Afiliação
  • Kuo PH; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Morris MJ; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Hesterman J; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Kendi AT; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Rahbar K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Wei XX; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Fang B; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Adra N; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Garje R; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Michalski JM; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Chi K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • de Bono J; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Fizazi K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Krause B; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Sartor O; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Tagawa ST; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Ghebremariam S; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Brackman M; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Wong CC; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Catafau AM; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Benson T; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Armstrong AJ; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
  • Herrmann K; From the University of Arizona, Tucson, Ariz (P.H.K.); Memorial Sloan-Kettering Cancer Center, New York, NY (M.J.M.); Invicro, Needham, Mass (J.H.); Mayo Clinic, Rochester, Minn (A.T.K., O.S.); Department of Nuclear Medicine, University Hospital Münster, Münster, Germany (K.R.); West German Cancer C
Radiology ; 312(2): e233460, 2024 08.
Article em En | MEDLINE | ID: mdl-39162634
ABSTRACT
Background Lutetium 177 [177Lu]Lu-PSMA-617 (177Lu-PSMA-617) is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Quantitative PSMA PET/CT analysis could provide information on 177Lu-PSMA-617 treatment benefits. Purpose To explore the association between quantitative baseline gallium 68 [68Ga]Ga-PSMA-11 (68Ga-PSMA-11) PET/CT parameters and treatment response and outcomes in the VISION trial. Materials and Methods This was an exploratory secondary analysis of the VISION trial. Eligible participants were randomized (June 2018 to October 2019) in a 21 ratio to 177Lu-PSMA-617 therapy (7.4 GBq every 6 weeks for up to six cycles) plus standard of care (SOC) or to SOC only. Baseline 68Ga-PSMA-11 PET parameters, including the mean and maximum standardized uptake value (SUVmean and SUVmax), PSMA-positive tumor volume, and tumor load, were extracted from five anatomic regions and the whole body. Associations of quantitative PET parameters with radiographic progression-free survival (rPFS), overall survival (OS), objective response rate, and prostate-specific antigen response were investigated using univariable and multivariable analyses (with treatment as the only other covariate). Outcomes were assessed in subgroups based on SUVmean quartiles. Results Quantitative PET parameters were well balanced between study arms for the 826 participants included. The median whole-body tumor SUVmean was 7.6 (IQR, 5.8-9.9). Whole-body tumor SUVmean was the best predictor of 177Lu-PSMA-617 efficacy, with a hazard ratio (HR) range of 0.86-1.43 for all outcomes (all P < .001). A 1-unit whole-body tumor SUVmean increase was associated with a 12% and 10% decrease in risk of an rPFS event and death, respectively. 177Lu-PSMA-617 plus SOC prolonged rPFS and OS in all SUVmean quartiles versus SOC only, with no identifiable optimum among participants receiving 177Lu-PSMA-617. Higher baseline PSMA-positive tumor volume and tumor load were associated with worse rPFS (HR range, 1.44-1.53 [P < .05] and 1.02-1.03 [P < .001], respectively) and OS (HR range, 1.36-2.12 [P < .006] and 1.04 [P < .001], respectively). Conclusion Baseline 68Ga-PSMA-11 PET/CT whole-body tumor SUVmean was the best predictor of 177Lu-PSMA-617 efficacy in participants in the VISION trial. Improvements in rPFS and OS with 177Lu-PSMA-617 plus SOC were greater among participants with higher whole-body tumor SUVmean, with evidence for benefit at all SUVmean levels. ClinicalTrials.gov identifier NCT03511664 Published under a CC BY 4.0 license. Supplemental material is available for this article.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Dipeptídeos / Neoplasias de Próstata Resistentes à Castração / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Isótopos de Gálio / Radioisótopos de Gálio / Compostos Heterocíclicos com 1 Anel / Lutécio Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Compostos Radiofarmacêuticos / Dipeptídeos / Neoplasias de Próstata Resistentes à Castração / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada / Isótopos de Gálio / Radioisótopos de Gálio / Compostos Heterocíclicos com 1 Anel / Lutécio Limite: Aged / Humans / Male / Middle aged Idioma: En Ano de publicação: 2024 Tipo de documento: Article